However, single-agent treatment using monoclonal antibodies against PD-1 or PD-L1 generally reported mediocre efficacy in breast cancer patients since most breast cancer tumors have long been classified as immunologically “cold.” “Cold” tumors are highly unresponsive to immunotherapy treatment (Szekely et al., 2018). This evidence concerns the gene CD274 and breast carcinoma.